Human Spheroid-Qualified Hepatocytes
Closed Solicitation Posted
- Solicitation number
- 75N95023Q00508
- Agency
- National Institute on Drug Abuse National Institutes of Health, Department of Health and Human Services
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 325414 Biological Product (except Diagnostic) Manufacturing
- PSC
- 6505 Drugs And Biologicals
Notice details come from SAM.gov. Updated .
About this opportunity
The National Institute on Drug Abuse (NIDA) intends to award a non-competitive contract to Life Technologies Corporation for the purchase of 50 vials of Human Spheroid-Qualified Hepatocytes. These cells, which have been previously used in the project, are required to ensure consistent data and continuity in the Antiviral Program for Pandemics (APP) run by the National Center for Advancing Translational Sciences (NCATS). The hepatocytes will be used in the identification of antivirals and the development of microphysiological systems for second-line drug screening.
Products and Services:
- Supply of Human Spheroid-Qualified Hepatocytes.
- Delivery of 50 vials of cryopreserved, primary human liver cells (non-fetal).
- Assurance of consistency and continuity in the Antiviral Program for Pandemics.
- Support in the identification of direct acting antivirals.
- Assistance in the development of microphysiological systems for second-line drug screening.
Notice text
THIS IS A NON-COMPETITIVE (NOTICE OF INTENT) COMBINED SYNOPSIS SOLICITATION TO AWARD A CONTRACT OR PURCHASE ORDER WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME).
The National Institute on Drug Abuse (NIDA), Office of Acquisition (OA), on behalf of the National Center for Advancing Translational Sciences (NCATS), intends to negotiate and award a purchase order without providing full and open competition for Human Spheroid-Qualified Hepatocytes from Life Technologies Corporation, 5781 Van Allen Way, Carlsbad, CA 92008. This acquisition is conducted as non-competitive for a commercial item or service and is conducted pursuant to FAR 13.106-1(b)(1).
The rationale for the brand-name justification: Human Spheroid-Qualified Hepatocytes from Life Technologies were used to optimize viral infection for this project. Since the assay was optimized using these Hepatocytes from Life Technologies and these Hepatocytes were previously used for this project, the Hepatocytes required in this acquisition must also come from Life Technologies to ensure consistent data and the continuity of science. Introducing cells from another vendor may introduce variables and skew the data. Therefore, the required Hepatocytes must come from Life Technologies and this solicitation is restricted to Life Technologies and its authorized resellers.
The National Center for Advancing Translational Sciences (NCATS), within the National Institutes of Health (NIH), requires 50 vials of cryopreserved, primary human liver cells (non-fetal) to support the Antiviral Program for Pandemics (APP) program. NCATS works to identify direct acting antivirals towards viruses and for development of microphysiological systems (MPS) for second-line drug screening.
See attached Combined Synopsis / Solicitation and attachments for complete requirement details.
Attachments
| File | Type | Posted |
|---|---|---|
| D 1_FAR 52.212-1 (Mar 2023) (TAILORED).pdf | ||
| D 4_FAR 52.212-5 (Jun 2023).pdf | ||
| D 5_Invoice and Payment Provisions With IPP (Mar 2023).pdf | ||
| D 3_FAR 52.225-2 (Oct 2022).pdf | ||
| D 75N95023Q00508_CSS.pdf | ||
| D 2_FAR 52.212-3 (Dec 2022).pdf |
On GovTribe
Work this opportunity on GovTribe
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity